|
Payors |
Hospitals |
Doctors |
Clinical Laboratories |
Patients |
ELSI |
FDA |
Orphan Acts |
CLIA |
Tort Law |
| Testing Pathogens |
Short and long term cost benefit; formulary restrictions; antibiotic
resistance |
Cost-benefit; speed; exposure to patients and providers; antibiotic
resistance |
Education; testing source; improvement in patient care; antibiotic
resistance |
Adherence to regulatory frameworks |
Cost-benefit; improvement in care; antibiotic resistance |
Patient confidentiality; public health |
Necessary approvals; safety & efficacy |
Dependent on frequency |
Setting and communicating standards |
Standard of care |
| Testing Tumors |
Clearer diagnosis; improved outcomes; formulary restrictions |
Speed; efficacy of treatment; reduction in side effects and intensive
care |
Education; testing options; better outcomes; drug resistance |
Adherence to regulatory frameworks; new technologies |
Improvement in care and outcome; fewer side effects; clear diagnosis |
Access to treatment options |
Necessary approvals; safety & efficacy |
Dependent on frequency |
Setting and communicating standards |
Standard of care |
Testing Inherited Genomes
Prediction
Diagnosis
Prognosis
|
Mobile populations; long-term cost-benefit; coverage and risk
stratification |
Ability to treat; cost-benefit |
Education; patient counseling; treatment options |
Adherence to regulatory frameworks; screening test quality |
Treatment options; implications for family members; test quality; coverage;
discrimination |
Patient confidentiality; inappropriate use of information; family
members |
Necessary approvals; utility, safety and efficacy |
Dependent of frequency; ability to treat |
Setting and communicating standards; patient protection |
Standard of care; misuse of information |
Treatment
Safety
Efficacy
|
Short and long term cost-benefit; formulary restrictions |
Cost benefit; speed; in-house v. outsourced testing |
Education; speed; testing source; improvement in patient care; prescription
delay |
Adherence to regulatory frameworks; new technologies |
Cost benefit; implications for family members |
Patient confidentiality; access to 'individualized' medicines |
Cross-division review structure; safety & efficacy of combined test and
treatment |
Dependent on frequency |
Setting and communicating standards |
Standard of care |
| Patient Curiosity |
|
|
|
|
|
|
|
|
|
|
| Research |
|
Sample banking; Medical records privacy; Informed consent |
|
|
|
Data handling/privacy; Informed consent; Sample banking |
|
|
|
Human subjects regulations; Medical record privacy |
